Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
IMRX Stock Chart & Stats
$6.08
-$0.24(-10.17%)
At close: 4:00 PM EST
$6.08
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$1.10 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)1.27M
Market Cap
$471.36M
Enterprise Value$54.04M
Total Cash (Recent Filing)$227.56M
Total Debt (Recent Filing)$3.92M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Mar 11, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding64,569,970
10 Day Avg. Volume1,342,150
30 Day Avg. Volume1,267,159
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.59
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-153.25
Enterprise Value/Ebitda-0.86
Forecast
1Y Price Target
$17.60Price Target Upside189.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe main update from earnings was two new case studies from the ongoing Ph 2a studies for atebimetinib plus mFFX where one patient achieved CR and another patient was able to undergo curative-intent Whipple based on the deep response to the atebimetinib combo.
Future DevelopmentsManagement reiterated that its focus remains on atebimetinib plus mGnP combo in 1L PDAC, for which, the Ph 3 study will be initiated in the future.
Investment And PartnershipsRecent $25M private placement and the agreement to study a combination of its drug with Lilly’s KRAS G12C in NSCLC show promising developments for the company.
Bears Say
Safety Profile ConcernsThe safety profile deteriorated slightly with higher percentages of neutropenia, anemia, and fatigue.
Immuneering News
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.10 and its highest was $10.08 in the past 12 months.
What is Immuneering’s market cap?
Immuneering’s market cap is $471.36M.
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is Mar 11, 2026 which is in 87 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Nov 12, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.388 by $0.008.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -0.31.
How many shares outstanding does Immuneering have?
Immuneering has 64,569,970 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.388. Following the earnings report the stock price went down -2.568%.
Which hedge fund is a major shareholder of Immuneering?
Currently, no hedge funds are holding shares in IMRX
Immuneering Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.60 (189.47% Upside)
$17.60 (189.47% Upside)
Insider Transactions
Bought Shares
Worth $152.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
245.97%
12-Months-Change
Fundamentals
Return on Equity
-43.75%
Trailing 12-Months
Asset Growth
251.61%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corporation (IMRX) is a biopharmaceutical company focused on developing innovative drug candidates for the treatment of cancer and other diseases. The company's approach is centered around its proprietary platform that harnesses computational biology to unravel complex biological data and identify potential therapeutic targets. Immuneering aims to advance precision medicine by creating effective treatments that can precisely target specific disease pathways, offering new hope for patients with unmet medical needs.
IMRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong positive updates, with remarkable clinical trial results and significant financial and strategic developments. While there are some challenges with specific treatments and regulatory timelines, the overall sentiment is positive due to the company's promising progress and future potential.View all IMRX earnings summariesIMRX Stock 12 Month Forecast
Average Price Target
$17.60
▲(189.47% Upside)
Technical Analysis
Larimar Therapeutics
―
Rocket Pharmaceuticals
―
I-MAB
―
Invivyd
―
Aura Biosciences Inc
―
Ownership Overview
10.03% Insiders
3.03% Mutual Funds
7.50% Other Institutional Investors
75.88% Public Companies and
Individual Investors